Platelets, thrombosis and drugs.

Abstract:

:The development of thrombosis involves 4 main factors: the vessel wall, the formed elements of the blood, blood coagulation, and blood flow. In venous thrombosis, however, the major part in both the initiation and growth of thrombi is played by the platelets. In selecting drugs which inhibit platelet function it is helful to know which of the platelet reactions that contribute to thrombus formation can be inhibited by various agents. Platelets adhere to the damaged vessel wall, collagen being probably the most important constituent involved. They are then stimulated to release the contents of their storage granules. Release-inducing agents promote the discharge of adenosine diphosphate (ADP) which causes platelets in the vicinity to swell to a more spherical shape, extend pseudopods and adhere to each other. Platelet aggregation is reversible, and a number of drugs have been shown to be capable of inhibiting platelet function at various stages, both in vitro and in vivo. Adrenaline, noradrenaline, oestrogens and nicotine enhance aggregation. Drugs which inhibit platelet function include the non-steroidal anti-inflammatory drugs, the pyrimido-pyrimidines (e.g. dipyridamole), hydroxychloroquine, clofibrate, and dextran. In this review the effects of drugs which inhibit platelet function are outlined and the extent to which they can be used to influence the course of thromboembolic disease in man is discussed. It is suggested that combination of anti-platelet drugs with anticoagulants could prove clinically useful.

journal_name

Drugs

journal_title

Drugs

authors

Mustard JF,Packham MA

doi

10.2165/00003495-197509010-00003

subject

Has Abstract

pub_date

1975-01-01 00:00:00

pages

19-76

issue

1

eissn

0012-6667

issn

1179-1950

journal_volume

9

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Ebastine in context. Introduction.

    abstract::The allergic reaction to a specific antigen is characterised by a series of complex immunological processes consisting of an early specific immune response and a late inflammatory reaction. The release of active substances (principally histamine) from cytoplasmic granules of mast cells and basophils in response to ant...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199600521-00003

    authors: Buendia E

    更新日期:1996-01-01 00:00:00

  • The role of vasodilator therapy in the treatment of severe chronic heart failure.

    abstract::The rationale for the use of vasodilating agents in the treatment of congestive heart failure is to reverse the systemic vasoconstriction that characterises patients with this disorder, and which may further limit cardiac performance. Nitrates were the first vasodilators used, followed by arterial vasodilators (hydral...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198600325-00003

    authors: Packer M

    更新日期:1986-01-01 00:00:00

  • Postoperative ileus: progress towards effective management.

    abstract::The pathogenesis of postoperative ileus (PI) is multifactorial, and includes activation of inhibitory reflexes, inflammatory mediators and opioids (endogenous and exogenous). Accordingly, various strategies have been employed to prevent PI. As single-modality treatment, continuous postoperative epidural analgesia incl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262180-00004

    authors: Holte K,Kehlet H

    更新日期:2002-01-01 00:00:00

  • Pemphigus vulgaris: an evidence-based treatment update.

    abstract:BACKGROUND:While a variety of intervention options have been described for pemphigus vulgaris, the optimal treatment strategy has not been established. OBJECTIVES:The objective of this systematic review is to assess the literature on the efficacy and safety of interventions for the treatment of pemphigus vulgaris. DA...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0353-6

    authors: Zhao CY,Murrell DF

    更新日期:2015-02-01 00:00:00

  • Interaction of lipoproteins with the artery wall.

    abstract::Atherosclerosis can be defined in terms of the processes involved rather than in morphological terms, and there is evidence for possible roles of the macrophage in atherogenesis. The relevance of hyperlipidaemia to the morphogenesis of the atherosclerotic plaque is important, and this has been described in animal mode...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800363-00012

    authors: Woolf N

    更新日期:1988-01-01 00:00:00

  • [Clinical experience with nifedipine in the treatment of angina pectoris in Japan].

    abstract::Developed by Bayer in Germany, nifedipine was shown to be effective in the treatment of patients with angina pectoris by Japanese investigators. Professor Kimura first reported the efficacy of nifedipine in patients with angina pectoris and those findings have been replicated in numerous trials conducted since then. C...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666991-00003

    authors: Hosoda S

    更新日期:2006-01-01 00:00:00

  • Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.

    abstract::The article Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension, written by Sheridan Hoy, was originally published Online First without open access. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-018-0925-3

    authors: Hoy SM

    更新日期:2018-06-01 00:00:00

  • Torasemide. A review of its pharmacological properties and therapeutic potential.

    abstract::Torasemide (torsemide) is a high-ceiling loop diuretic which acts on the thick ascending limb of the loop of Henle to promote rapid and marked excretion of water, sodium and chloride. Like furosemide (frusemide), its major site of action is from the luminal side of the cell. Torasemide is at least twice as potent as f...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199141010-00008

    authors: Friedel HA,Buckley MM

    更新日期:1991-01-01 00:00:00

  • Entecavir: a review of its use in chronic hepatitis B.

    abstract::Entecavir (Baraclude) is a novel nucleoside analogue of 2'-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus (HBV). In large, randomised, double-blind, phase III clinical trials in patients with chronic HBV infection, oral entecavir 0.5 or 1.0mg once daily for up to 96 ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666120-00009

    authors: Robinson DM,Scott LJ,Plosker GL

    更新日期:2006-01-01 00:00:00

  • Vitamin A acid: a review of its pharmacological properties and therapeutic use in the topical treatment of acne vulgaris.

    abstract::Vitamin A acid (retinoic acid: tretinoin) is a vitamin A derivative used in the topical treatment of acne. It acts by 'unseating' comedones, improvement developing slowly over a period of 2 to 3 or more months, and is also said to prevent the formation of new lesions. About three-quarters of patients with acne vulgari...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197714060-00001

    authors: Heel RC,Brogden RN,Speight TM,Avery GS

    更新日期:1977-12-01 00:00:00

  • Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

    abstract::Alfuzosin, a new quinazoline derivative, acts as a selective and competitive antagonist of alpha 1-adrenoceptor-mediated contraction of prostatic, prostatic capsule, bladder base and proximal urethral smooth muscle, thereby reducing the tone of these structures. Consequently, urethral pressure and resistance, bladder ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199345030-00008

    authors: Wilde MI,Fitton A,McTavish D

    更新日期:1993-03-01 00:00:00

  • Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification.

    abstract::Although vasodilator drugs are of proven worth in the management of patients with severe heart failure, a useful system of classification of vasodilator drugs has not yet been devised. The traditional system of classification based on the dominant arterial and/or venous sites of action as determined by limb plethysmog...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198224010-00003

    authors: Packer M

    更新日期:1982-07-01 00:00:00

  • Pancreatic islet cell transplantation: likely impact on current therapeutics for type 1 diabetes mellitus.

    abstract::Pancreatic islet transplantation as a cell-based treatment for diabetes mellitus has been pursued for over quarter of a century, ever since the first successful use of this approach to cure diabetes mellitus in rodents in the 1970s. However, even though autoislet intrahepatic transplantation in patients with chronic p...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200161140-00001

    authors: Robertson RP

    更新日期:2001-01-01 00:00:00

  • Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.

    abstract::Nadroparin calcium is a low molecular weight heparin with a mean molecular weight of 4.5 kD. Compared with unfractionated heparin, nadroparin calcium has a greater ratio of anti-factor Xa/anti-factor IIa activity. Nadroparin calcium has a longer half-life and greater bioavailability than unfractionated heparin and can...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199244050-00010

    authors: Barradell LB,Buckley MM

    更新日期:1992-11-01 00:00:00

  • Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

    abstract::Isradipine, a dihydropyridine derivative, inhibits the inward calcium flux through 'slow' channels of cardiac and vascular tissue, thereby eliciting potent coronary, cerebral and peripheral vasodilatation. In comparison with other calcium channel blockers the drug offers the advantages of minimal cardiodepressant acti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040010-00004

    authors: Fitton A,Benfield P

    更新日期:1990-07-01 00:00:00

  • Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.

    abstract::Sitagliptin (Januvia(®), Xelevia™, Glactiv(®), Tesavel(®)) is an orally administered, potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first agent of its class to be approved for use in the management of adults with type 2 diabetes. Numerous randomized placebo- or active comparator-c...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0169-1

    authors: Plosker GL

    更新日期:2014-02-01 00:00:00

  • The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders.

    abstract::This review focuses on the biochemical and clinical aspects of methylation in neuropsychiatric disorders and the clinical potential of their treatment with ademetionine (S-adenosylmethionine; SAMe). SAMe is required in numerous transmethylation reactions involving nucleic acids, proteins, phospholipids, amines and oth...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199448020-00002

    authors: Bottiglieri T,Hyland K,Reynolds EH

    更新日期:1994-08-01 00:00:00

  • Correction to: Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer.

    abstract::The article Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer, written by Connie Kang, Sohita Dhillon and Emma D. Deeks, was originally published Online First without open access. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-019-01199-6

    authors: Kang C,Dhillon S,Deeks ED

    更新日期:2019-10-01 00:00:00

  • Macitentan: a review of its use in patients with pulmonary arterial hypertension.

    abstract::Macitentan (Opsumit(®)) is an orally active, dual endothelin receptor antagonist (ERA) with tissue targeting properties. Macitentan was approved recently in the EU (as monotherapy or combination therapy) for the long-term treatment of pulmonary arterial hypertension (PAH) in adults of WHO functional class II or III, a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0266-9

    authors: Dhillon S

    更新日期:2014-09-01 00:00:00

  • Panic disorder. Pathophysiology and drug treatment.

    abstract::Advances over the past 2 decades in our understanding of the biology of panic disorder have paralleled a remarkable increase in the development of new pharmacological agents with antipanic effects. Although we can not presently use biological tests to help with our choice of therapeutic agent for individual patients, ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549030-00002

    authors: Johnson MR,Lydiard RB,Ballenger JC

    更新日期:1995-03-01 00:00:00

  • Diquafosol ophthalmic solution 3 %: a review of its use in dry eye.

    abstract::Diquafosol ophthalmic solution 3 % (Diquas(®)) is a P2Y2 receptor agonist that promotes tear fluid and mucin secretion and is currently approved in Japan and South Korea for the treatment of dry eye. In randomized, double-blind, multicentre trials in patients with dry eye, significantly greater improvements in fluores...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0409-7

    authors: Keating GM

    更新日期:2015-05-01 00:00:00

  • Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis.

    abstract::Glucocorticoids (GCs) are often used for improvement of quality of life, particularly in the elderly, but long-term GC use may cause harm; bone loss and fractures are among the most devastating side effects. Fracture risk is particularly high in patients with a severe underlying disease with an urgent need for treatme...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01145-6

    authors: Raterman HG,Bultink IEM,Lems WF

    更新日期:2019-07-01 00:00:00

  • Management of Thrombotic Complications in COVID-19: An Update.

    abstract::Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily affects the respiratory tract and causes lung injury characterized by acute respiratory distress syndrome. Although the pathophysiology of COVID-19 is not yet clea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01377-x

    authors: Hajra A,Mathai SV,Ball S,Bandyopadhyay D,Veyseh M,Chakraborty S,Lavie CJ,Aronow WS

    更新日期:2020-10-01 00:00:00

  • Hepatitis E vaccines: progress and prospects.

    abstract::Hepatitis E accounts for the major part of enterally transmitted non-A, non-B hepatitis worldwide. Its agent, the hepatitis E virus (HEV), is a small, single-stranded RNA virus. Only one serotype of HEV is recognised. Infection results in protective immunity with long-lived neutralising antibodies. In developing count...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464140-00002

    authors: Worm HC,Wirnsberger G

    更新日期:2004-01-01 00:00:00

  • Meningococcal groups C and Y and haemophilus B tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix(®)): a review.

    abstract::The meningococcal groups C and Y and Haemophilus b (Hib) tetanus toxoid conjugate vaccine (HibMenCY-TT) contains Neisseria meningitidis serogroup C and Y capsular polysaccharide antigens, and Hib capsular polysaccharide [polyribosyl-ribitol-phosphate (PRP)]. The HibMenCY-TT vaccine is available in the USA for use as a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0048-9

    authors: Perry CM

    更新日期:2013-05-01 00:00:00

  • Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

    abstract::Iloprost is an analogue of epoprostenol (prostacyclin; PGI2; a potent but short-lived prostanoid mainly produced in the vascular endothelium) and mimics the pharmacodynamic properties of this compound, namely: inhibition of platelet aggregation, vasodilatation and, as yet ill-defined, cytoprotection. Improved metaboli...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199243060-00008

    authors: Grant SM,Goa KL

    更新日期:1992-06-01 00:00:00

  • Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations.

    abstract::Platinum-based doublet chemotherapy with or without bevacizumab is the standard of care for the initial management of advanced and metastatic non-small cell lung cancer (NSCLC) without a targetable molecular abnormality. However, the majority of patients with NSCLC will ultimately develop resistance to initial platinu...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0628-6

    authors: Barnfield PC,Ellis PM

    更新日期:2016-09-01 00:00:00

  • Panobinostat: first global approval.

    abstract::Novartis has developed oral and intravenous formulations of panobinostat (Farydak(®)), a histone deacetylase (HDAC) inhibitor, for the treatment of cancer. HDACs have important roles in maintaining chromatin structure and in regulating gene expression, including that of tumour suppressor genes, and thus represent vali...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0388-8

    authors: Garnock-Jones KP

    更新日期:2015-04-01 00:00:00

  • Tenapanor: First Approval.

    abstract::The selective sodium hydrogen exchanger 3 (NHE3) inhibitor tenapanor is being developed by Ardelyx Inc. for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) [under the tradename IBSRELA®] and for hyperphosphataemia in patients with chronic kidney disease (CKD) on dialysis or with end stage re...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01215-9

    authors: Markham A

    更新日期:2019-11-01 00:00:00

  • Drugs affecting the inner ear. A review of their clinical efficacy, mechanisms of action, toxicity, and place in therapy.

    abstract::Many drugs have a site of action within the inner ear. The list includes therapeutic, diagnostic and ototoxic agents. Therapeutic agents are most useful in cases of infections, endolymphatic hydrops, vascular insufficiency, vertigo of peripheral origin, autoimmune disease, otosclerosis (otospongiosis), sudden hearing ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198836060-00005

    authors: Norris CH

    更新日期:1988-12-01 00:00:00